首页 | 本学科首页   官方微博 | 高级检索  
     

四种非传染性肝病的体检人员肝脏相关血清学标志物的调查分析
引用本文:黄宴萍,许平,罗雨田,汪周天,许瑞家,赵秋玲,周继昌. 四种非传染性肝病的体检人员肝脏相关血清学标志物的调查分析[J]. 安徽医药, 2023, 27(12): 2384-2388
作者姓名:黄宴萍  许平  罗雨田  汪周天  许瑞家  赵秋玲  周继昌
作者单位:深圳市萨米医疗中心深圳市第四人民医院健康管理部,广东深圳 518118;深圳市宝安区疾病预防控制中心,广东深圳 518101;哥伦比亚大学公共卫生学院,纽约 10025;中山大学公共卫生学院,广东深圳 518107
基金项目:国家自然科学基金项目( 81973038)
摘    要:目的 探究体检人群中脂肪肝、肝囊肿、肝血管瘤、脂肪肝合并肝囊肿的肝脏相关血清学标志物。方法 以深圳市萨米医疗中心2018年9月至2020年8月的体检人群为研究对象,根据肝胆B超检查结果,肝病可分为单一肝病和肝病合并症,因而分为对照组和4个非传染性肝病组,采用Mann-Whitney U检验,比较各组的肝功能和血脂指标。结果 共纳入8 938例体检者(男性n=4 986,女性n=3 952)为研究对象。男性中,脂肪肝组高密度脂蛋白胆固醇(HDLC)1.10(0.96,1.26)mmol/L低于对照组1.33(1.14,1.53)mmol/L(P<0.05),丙氨酸氨基转移酶(ALT)30.7(21.8,45.0)U/L、天门冬氨酸氨基转移酶(AST)22.0(18.3,27.6)U/L、总胆固醇5.18(4.59,5.81)mmol/L、低密度脂蛋白胆固醇(LDLC)3.40(2.85,3.98)mmol/L高于对照组[19.0(14.1,26.3)U/L、19.0(16.4,22.3)U/L、4.81(4.28,5.38)mmol/L、3.11(2.62,3.65)mmol/L]...

关 键 词:脂肪肝  肝囊肿  肝血管瘤  肝功能  血脂  诊断,鉴别

Analysis of liver-related serologic markers of four noninfectious liver diseases in the health examination population
HUANG Yanping,XU Ping,LUO Yutian,WANG Zhoutian,XU Ruiji,ZHAO Qiuling,ZHOU Jichang. Analysis of liver-related serologic markers of four noninfectious liver diseases in the health examination population[J]. Anhui Medical and Pharmaceutical Journal, 2023, 27(12): 2384-2388
Authors:HUANG Yanping  XU Ping  LUO Yutian  WANG Zhoutian  XU Ruiji  ZHAO Qiuling  ZHOU Jichang
Affiliation:Health Management Department in Shenzhen Samii Medical Center The Fourth People''s Hospi.tal of Shenzhen, Shenzhen, Guangdong 518118, China;Bao''an Center for Disease Control and Prevention, Shenzhen, Guangdong 518101, China;School of Public Health, Columbia University, New York 10025;School of Public Health , Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong 518107, China
Abstract:Objective To explore liver-related serologic markers of fatty liver, hepatic cysts, hepatic hemangioma, and fatty livercombined with hepatic cysts in a health examination population.Methods The health examination population of Shenzhen Samii Med.ical Center from September 2018 to August 2020 was used as the study population. According to the results of hepatobiliary B-ultra. sound, liver disease can be divided into single liver disease and liver disease complications and thus divided into a control group andfour noninfectious liver disease groups, and the Mann-Whitney U test was used to compare the liver function and lipid indices of each group.Results A total of 8 938 subjects included (male n= 4 986 and female n =3 952) with health examination were included in the study. In males, high-density lipoprotein cholesterol (HDLC) of 1.10 (0.96, 1.26) mmol/L in the fatty liver group was lower than that ofthe control group of 1.33 (1.14, 1.53) mmol/L (P<0.05), and alanine aminotransferase (ALT) of 30.7 (21.8, 45.0) U/L, aspartate amino.transferase (AST) of 22.0 (18.3, 27.6) U/L, total cholesterol of 5.18 (4.59, 5.81) mmol/L, low density lipoprotein cholesterol (LDLC) of 3.40 (2.85, 3.98) mmol/L in the fatty liver group were higher than those in the control group [19.0 (14.1, 26.3) U/L, 19.0 (16.4, 22.3) U/L, 4.81 (4.28, 5.38) mmol/L, 3.11 (2.62, 3.65) mmol/L] (P<0.05); ALT of 24.0 (18.0, 35.0) U/L, AST of 21.0 (18.0, 26.0) U/L and HDLCof 1.00 (1.00, 1.00) mmol/L of the fatty liver combined with hepatic cyst group were lower than those in the fatty liver group [30.7 (21.8,45.0) U/L, 22.0 (18.3, 27.6) U/L, 1.10 (0.96, 1.26) mmol/L] (P<0.05), and HDLC of 1.00 (1.00, 1.00) mmol/L was lower than that in the hepatic cyst group of 1.31 (1.13, 1.52) mmol/L (P<0.05), ALT of 24.0 (18.0, 35.0) U/L, AST of 21.0 (18.0, 26.0) U/L and total cholester.ol of 5.00 (5.00, 6.00) mmol/L were higher than those in the hepatic cyst group [18.5 (14.8, 24.0) U/L, 19.2 (16.6, 22.3) U/L and 4.88(4.29, 5.63) mmol/L] (P<0.05). In females, HDLC of 1.31 (1.14, 1.48) mmol/L in the fatty liver group was lower than that in the controlgroup of 1.61 (1.41, 1.83) mmol/L (P<0.05), and ALT of 17.5 (13.1, 24.8) U/L, AST of 17.9 (15.2, 22.4) U/L, total cholesterol of 5.10(4.52, 5.76) mmol/L, LDLC of 3.36 (2.74, 3.93) mmol/L in the fatty liver group were higher than those in the control group [11.3 (9.0,14.9) U/L, 16.2 (14.2, 18.7) U/L, 4.52 (4.05, 5.05) mmol/L, 2.70 (2.28, 3.18) mmol/L] (P<0.05); total cholesterol of 4.77 (4.28, 5.40)mmol/L and LDLC of 2.88 (2.48, 3.38) mmol/L in the hepatic cyst group were higher than those in the control group [4.52 (4.05, 5.05)and 2.70 (2.28, 3.18) mmol/L] (P<0.05). There was no statistically significant difference between the liver function and lipid indices inthe hepatic hemangioma group and control group (P>0.05); the HDLC of 1.00 (1.00, 1.00) mmol/L in the fatty liver combined with he.patic cyst group was lower than that of the fatty liver group [1.31 (1.14, 1.48) mmol/L] and that of the hepatic cyst group [1.61 (1.39,1.84) mmol/L](P<0.05); ALT of 18.0 (14.0, 28.0) U/L and AST of 20.0 (16.0, 22.0) U/L in the fatty liver combined with hepatic cystgroup were higher than those of the liver cyst group [11.6 (9.2, 15.7) U/L and 16.4 (14.2, 19.4) U/L] (P<0.05).Conclusion The liver function and lipid indices were ideal for the diagnosis and monitoring of fatty liver and fatty liver combined with hepatic cyst but are ofmore limited significance in simple hepatic cysts or hepatic hemangioma.
Keywords:Fatty liver   Hepatic cyst   Hepatic hemangioma   Liver function   Blood lipids   Diagnosis, differential
点击此处可从《安徽医药》浏览原始摘要信息
点击此处可从《安徽医药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号